Yuhan Corporation

Korea Institute of Ocean Science & Technology

Janssen Biotech, Inc.

Kakao Corporation

Sol Park

Hyun Ho Choi

Tae Dong Han

Eun Kyung Kim

Na Ry Ha

Hee Jae Tak

Su Bin Choi

Dong Hoon Kim

Mi Kyeong Ju

Tae Wang Kim

So Young Kim

Eun Hye Jung

Eui Chul Lee

Jong Seok Lee

Ji Hoon Lee

Yeon Ju Lee

Hyi Seung Lee

Hee Jae Shin

Cheol Hee Lim

Hyok Jun Cho

Da Na Jeong

Bo Hyun Mun

Dan Bi Sung

Na Yeon Yang

Scott D Kuduk

Mi Ok Kim

Jae Young Sim

Hee Jin Lim

Kwan Hoon Hyun

Hyunjoo Lee

Young Ae Yoon

James Campbell Robertson

Marian C Bryan

Gyu Jin Lee

Misong Kim

Tae Kyun Kim

Eun Joo Kim

Byoungmoon Lee

Jeong Hyun Yang

Eui Chui Lee

Heejun Kim

Eun Ha Ahn

Sung Hyun Choi

Sung Bum Hong

Cheol Wong Kam

Disclosed are a method for synthesizing a thieno[3,2-b]pyridine-5(4H)-one derivative by using a gold catalyst and a use of the derivative compound, wherein the novel thieno[3,2-b]pyridine-5(4H)-one derivative of the present disclosure, which is a compound synthesized using gold as a catalyst, has fluorescence characteristics with a wide range of emission wavelengths and thus can be helpfully used in various industrial fields, such as physics, chemistry, and biomedicine research.

Method for synthesizing thieno[3,2-b]pyridine-5(4H)-one derivative compound, using gold catalyst, and use therefor

Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

Substituted aminopyridine compounds as EGFR inhibitors

The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolopyridin-3-ones or their salts and pharmaceutical compositions comprising the same

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Triazolone derivatives or salts thereof and pharmaceutical compositions comprising the same

The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

3,3-difluoroallylamines or salts thereof and pharmaceutical compositions comprising the same

The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Aryl or heteroaryl triazolone derivatives or salts thereof, or pharmaceutical compositions comprising the same

The present invention relates to a novel thieno[3,2-b]pyridine-5(4H)-one derivative compound, a preparation method thereof, and a use thereof. The novel thieno[3,2-b]pyridine-5(4H)-one derivative compound according to the present invention is synthesized via an aza-[3+3] cyclization addition reaction using BOP, wherein the compound is obtained by synthesizing a 4-arylthiophen-3-amine in which aryl groups such as 4-piperidyl-C6H4, 4-pyrrolidyl-C6H4, 4-MeOC6H4, 3,4,5-(MeO)3C6H4, C6H5, 4-C6H5C6H4, and 4-F3COC6H4 are introduced via a synthesis process by a bromination reaction, a hydrolysis reaction, a decarboxylation reaction, and a Suzuki coupling reaction of methyl 3-aminothiophene carboxylate, and by synthesizing 4-arylthiophen-3-amine and mono-methyl fumarate via a formal aza-[3+3] cyclization addition reaction using BOP and conjugation. Accordingly, novel thieno[3,2-b]pyridine-5(4H)-one derivative compounds according to the present invention have fluorescence properties with a wide range of emission wavelengths and thus may be utilized in various industrial fields such as physics, chemistry, and biomedical research.

Thieno[3,2-b]pyridine-5(4H)-one derivative compound, preparation method thereof and use thereof

The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Provided is an apparatus and method for providing a chatroom for consultation. The consultation chatroom providing apparatus generates an identification code by receiving consultation meta information and partner profile information from a partner server, generates a consultation chatroom by receiving the partner profile information and user information from a user terminal that scans or receives the identification code, and pushes information about the consultation chatroom to the user terminal.

Method and apparatus of providing chatrooms for consultation

Growing community of inventors

Yongin-si, South Korea

Sol Park